Brought to you by 
Ono licenses allogenic CAR-T cell therapy from Celyad
26 Jul 2016
Executive Summary
Celyad SA granted Ono Pharmaceutical Co. Ltd. exclusive rights to develop and sell its allogenic CAR T-cell therapy NKR2 for solid and blood cancers in Japan, South Korea, and Taiwan. Ono also gets an option to develop and sell autologous NKR2 in the same territories.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ono licenses allogenic CAR-T cell therapy from Celyad
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice